Novavax

Budrul Chukrut | Lightrocket | Getty ImagesVaccine maker Novavax on Wednesday reported fourth-quarter revenue and earnings that missed Wall Street's estimates and reiterated plans to cut costs as it fights to stay afloat. Still, Novavax narrowed its losses in the quarter from the same period a year ago, even as demand for the biotech company's Covid vaccine – its only marketable product – and other products that combat the virus continue to plummet worldwide. Here's what Novavax reported for the fourth quarter compared…

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Patrick Van Katwijk | Getty ImagesNovavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a canceled Covid vaccine purchase agreement. Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from…

…

Nikos Pekiaridis | Nurphoto | Getty ImagesStock Chart IconStock chart iconNovavax shares jump on news of a settlement payment from the Canadian government. It's unclear how many doses of Novavax's jab – its only commercially available product after 35 years – went unused. Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule. However, Canada can terminate the contract if Novavax fails to receive regulatory approval for vaccine production at the…

A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois.Scott Olson | Getty ImagesThe U.S. Food and Drug Administration's Covid strain selection for the next round of shots puts Pfizer, Moderna and Novavax on track to deliver new jabs in time for the fall – a decisive win for the vaccine makers as they gear up to compete against one another.  The FDA on Friday advised the…

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Patrick Van Katwijk | Getty ImagesShare prices of Novavax jumped about 30% on Tuesday after the biotech company unveiled promising new vaccine data and a broad cost-cutting push that includes major layoffs. The announcements are a sign of hope for investors after last quarter, when the company raised doubts about its ability to stay in…

Pfizer Inc. and its German partner BioNTech SE reported on Friday that their Omicron-tailored shot produced higher virus-neutralizing antibodies in older…

In this photo illustration a silhouette of a man holding a medical syringe and a vial seen displayed in front of the Novavax logo on a screen.Cezary Kowalski | Lightrocket | Getty ImagesNovavax posted an unexpected loss on Thursday but beat Wall Street's revenue expectations for the third quarter.The Covid-19 vaccine maker reported a net loss of more than $169 million for the third quarter, compared to a loss of $322 million in the same period last year.Novavax reported third quarter revenue of $735 million, a more than…

The Food and Drug Administration granted emergency authorization to Novavax Inc.’s Covid-19 shot as a booster for adults. The shot targets the original strain of the virus, whereas the updated booster shots from Moderna Inc. and Pfizer Inc. and its partner BioNTech SE, authorized in August by the FDA, target both the original strain and newer Omicron strains. The…

A box of the Novavax Covid-19 vaccine arranged at a pharmacy in Schwenksville, Pennsylvania, US, on Monday, Aug. 1, 2022.Bloomberg | Bloomberg | Getty ImagesBiotechnology company Novavax announced on Friday that its Covid-19 vaccine has been authorized for emergency use by the U.S Food and Drug Administration for adolescents between the ages of 12 and 17.In July, Novavax's two-dose Covid-19 vaccine for adults ages 18 and over got its emergency approval from the FDA.Having more vaccine options for adults and children will…